On Wednesday, July 3rd, SpectraCure presented results from the company's phase 1 study at the 17th International Photodynamic Association World Congress in Boston, USA. Johannes Swartling, CTO of SpectraCure held the presentation after an invitation from the conference organizers. The lecture was well attended and received with great interest.
The conference was attended by a total of 450 participants. Host of the event was Professor Tayyaba Hasan, active at Harvard Medical School in Boston. Professor Hasan is also one of the inventors of verteporfin, the photosensitizing drug used by SpectraCure in combination with the company's equipment for laser light illumination of tumours, SpectraCure's P18 system with IDOSE® .
The methodology underlying SpectraCure's treatment was also noticed by the assignment of the international Photodynamic Associations finest award to Professor Avigdor Scherz, active at the Weizmann Institute, for his work in explaining the mechanisms of PDT treatment with vascular acting photosensitizing drugs, the class of drugs that includes verteporfin. "It is very pleasing that the methodology is rewarded with this price, it shows that SpectraCure's method is right in time and is considered to have good opportunities to make a real benefit to patients," comments Johannes Swartling, CTO of SpectraCure.
